45256BAE1
Impax Laboratories, Inc.
Could not find a ticker for this position, may be a filing error
A specialty pharmaceutical company that developed and marketed generic and branded medications, with a particular strength in controlled-release drug delivery. Founded in 1995 as Impax Pharmaceuticals, it took its name through a 1999 reverse merger with the publicly traded Global Pharmaceutical Corporation, and became known for Parkinson's disease treatments like Rytary. In 2018 it merged with Amneal Pharmaceuticals, ending its run as an independent company.
CONVERTIBLEUnderlying: IPXLCUSIP: 45256BAE1HealthcareUS1 derivative reporter
2.00% Convertible Senior Notes due June 15, 2022
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
